DRIO (DarioHealth) EBIT: $-33.40 Mil (TTM As of Mar. 2026)


DRIO DarioHealth Corp DRIO
62 GF Score
Price $6.06
GF Value $7.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is DarioHealth EBIT?

DarioHealth DRIO +1.17% 62 EBIT is $-33.40 Mil as of Mar. 2026. GuruFocus rates DRIO with a GF Score™ of 62/100 and a GF Value™ of $7.15 (Modestly Undervalued). The stock has 4 warning signs investors should review.

DarioHealth's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-7.04 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-33.40 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. DarioHealth's annualized ROC % for the quarter that ended in Mar. 2026 was -37.86%. DarioHealth's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2,363.42%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. DarioHealth's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -59.52%.

DarioHealth  (NAS:DRIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

DarioHealth's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-29.236 * ( 1 - 0% )/( (79.001 + 75.426)/ 2 )
=-29.236/77.2135
=-37.86 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=110.075 - 5.33 - ( 26.017 - max(0, 9.323 - 35.067+26.017))
=79.001

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=103.281 - 8.478 - ( 20.012 - max(0, 9.357 - 28.734+20.012))
=75.426

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

DarioHealth's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-28.172/( ( (1.266 + max(-0.628, 0)) + (1.118 + max(-2.336, 0)) )/ 2 )
=-28.172/( ( 1.266 + 1.118 )/ 2 )
=-28.172/1.192
=-2,363.42 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.144 + 4.316 + 1.805) - (5.33 + 0.714 + 2.849)
=-0.628

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.219 + 4.172 + 0.252) - (8.478 + 0.501 + 0)
=-2.336

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

DarioHealth's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-33.403/56.117
=-59.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DarioHealth EBIT Related Terms

DarioHealth EBIT Historical Data

* Premium members only.

The historical data trend for DarioHealth's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DarioHealth EBIT Chart

DarioHealth Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -76.73 -60.31 -56.19 -44.60 -38.59

DarioHealth Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.21 -9.20 -9.31 -7.85 -7.04

DRIO vs BEAT, ONMD, VASO: EBIT Comparison

For the Health Information Services subindustry, DarioHealth's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DarioHealth EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DarioHealth's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where DarioHealth's EV-to-EBIT falls into.


DRIO
62GF Score
DarioHealth Corp DRIO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DarioHealth EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-33.40 Mil mean?
DarioHealth (DRIO) has a EBIT of $-33.40 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on DarioHealth.
Is DarioHealth's EBIT too high?
DarioHealth's current EBIT is $-33.40 Mil. Overall, DarioHealth has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DarioHealth's EBIT compare to BEAT and ONMD?
DarioHealth's EBIT of $-33.40 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on DarioHealth. DarioHealth's current EBIT is $-33.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DarioHealth stock overvalued right now?
Based on GuruFocus' analysis, DarioHealth (DRIO) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.15, compared to a current price of $6.06 — trading 15.2% below its estimated fair value. The current EBIT is $-33.40 Mil. DarioHealth's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For DarioHealth (DRIO), the current EBIT is $-33.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DarioHealth (DRIO) Overvalued in 2026?

Based on GuruFocus' analysis, DarioHealth stock appears to be undervalued. The current stock price of $6.06 is trading 15.2% below its estimated GF Value™ of $7.15. GuruFocus considers DarioHealth to be Modestly Undervalued.

Key valuation signals for DRIO:

  • EBIT: $-33.40 Mil
  • GF Value™: $7.15 vs. price of $6.06 (15.2% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the DRIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DarioHealth Business Description

Address 322 West 57th Street, New York, NY, USA, 10019
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
62GF Score

Get the complete analysis for DRIO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.06
Price
$7.15
GF Value